Infertility

Latest News


CME Content


Results of a study of more than 116,000 women, published online May 14 in Human Reproduction reveal a 39% lower risk of endometriosis in those who were morbidly obese than in women with normal body mass index (BMI).

"Should all women freeze their eggs?" This question was posed by Marcelle Cedars, MD, during a Tuesday afternoon session at ACOG's 61st annual clinical meeting. In a session offering late-breaking news from SGO, the Society for Maternal-Fetal Medicine (SMFM), the American Urogynecologic Society (AUGS), and the Society for Reproductive Endocrinology and Infertility (SREI), Dr. Cedars pointed out that as of October 2012, ASRM no longer considers egg freezing experimental.

Immediate start of hormonal contraception may reduce unintended pregnancies and increase method continuation, but the evidence is limited, according to the findings of an intervention review conducted by the Cochrane Fertility Regulation Group.

A registry-based study by researchers at UC San Francisco (UCSF) has shown an association between BRCA1/2 mutations and early menopause. The findings, published in Cancer, suggest that women who carry the genetic defect may be at risk of earlier infertility.

New drugs, new research, new guidelines… there’s a lot for ob/gyns to look forward to in the coming year. Here, the leaders of seven ob/gyn societies share the most interesting, important, exciting things on their radar for 2013.

From ASRM’s removal of the ‘experimental’ label from the procedure of oocyte cryopreservation, to discoveries into the complex genetic processes involved in ovarian cancer, 2012 was another important year in ob/gyn research. Here, the leaders of seven major ob/gyn societies reflect on the most exciting research of the last year.

A study published online by the British Medical Journal has shown that women who undergo in vitro fertilization (IVF) are at increased risk of pulmonary embolism (PE) and venous thromboembolism (VTE) during the first trimester.

The available evidence that selective estrogen receptor modulators (SERMs) can reduce the size of fibroids or improve clinical symptoms is inconsistent, according to the results of an updated intervention review conducted by the Cochrane Menstrual Disorders and Subfertility Group.